Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Matthieu Mahévas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Referral Center for Autoimmune Cytopenias, Créteil University Hospital, Créteil, France. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, B-Cell Activating Factor, Purpura, Thrombocytopenic, Idiopathic, B-Cell Activation Factor Receptor. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation. Binding of B‐cell‐activating factor (BAFF) to its receptor (BAFF‐R) has been shown to lead to B‐cell differentiation, proliferation, and survival, with BAFF levels shown to be elevated in patients with ITP and wAIHA. Targeting the BAFF/BAFF‐R pathway could address unmet needs that remain for patients with ITP and wAIHA despite available treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Referral Center for Autoimmune Cytopenias, Créteil University Hospital, Créteil, France.
- Department of Inflammation and Immunity, Imperial College London, London, UK.
- Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Lindsley F Kimball Research Institute, New York Blood Center, New York, New York, USA.
- Department of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
ORCID-Profile: Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Mahévas, M., Cooper, N., McDonald, V., Yazdanbakhsh, K., & Barcellini, W. (2026). Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70460
Vancouver
Mahévas M, Cooper N, McDonald V, Yazdanbakhsh K, Barcellini W. Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70460
BibTeX
@article{Mahvas2026,
author = {Mahévas, Matthieu and Cooper, Nichola and McDonald, Vickie and Yazdanbakhsh, Karina and Barcellini, Wilma},
title = {Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70460}
}
EUVIMED